Prevention and Management of Complications With a Hyaluronic Acid-Calcium Hydroxyapatite Hybrid Injectable.

Background: A ready-to-use hyaluronic acid-calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA.

Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA-related complications.

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics.

Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a critical role in immunotherapy resistance, characterized by immune cell composition, regulatory factors, and tumor mutational burden.

SherpaPak Cardiac Transport System: Experience in Pediatric Heart Transplantation.

Introduction: The present study aimed to assess the clinical outcomes of pediatric heart transplant patients whose donor hearts were preserved with the SherpaPakCardiac Transport System.

Methods: All pediatric patients undergoing heart transplantation at our center between January 2020 and June 2024 were included and described. Vasoactive inotropic score (VIS) was calculated.

Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) which is HER2-positive (immunohistochemistry [IHC] score of 3+ or ISH positivity) or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2 overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 receptor status might change following T-DXd therapy.

Design: We retrospectively reviewed patients with MBC who received T-DXd at The University of Texas MD Anderson Cancer Center.

Multimodality Approach to a Neonate With a Pericardial Mass and a Hemorrhagic Pericardial Effusion.

A 7-week-old infant with a 1-week history of a SARS-CoV2 respiratory infection presented with tachypnea. Cardiomegaly was noted on chest roentgenogram. Echocardiogram showed a large pericardial effusion, with tamponade physiology and a large pericardial mass.